Why is there so much therapy-related AML and MDS and so little therapy-related CML?

Leukemia Research

Volumn 38, Issue 10, 2014, Pages 1162-1164

  Gale, Robert Peter ^a   Hlatky, Lynn ^b   Sachs, Rainer K ^c   Radivoyevitch, Tomas ^d,e  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

DNA damaging drugs; Radiation; Secondary leukemia; Therapy related leukemia

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTHRAQUINONE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; GYRASE INHIBITOR; MELPHALAN; NITROSOUREA; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER RADIOTHERAPY; CANCER RISK; CANCER THERAPY; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DNA DAMAGE; GENE MUTATION; HUMAN; IONIZING RADIATION; MYELODYSPLASTIC SYNDROME; NOTE; RADIATION INJURY; RISK FACTOR; CHEMICALLY INDUCED DISORDER; DNA-DAMAGING DRUGS; EDITORIAL; GENETICS; LEUKEMIA; RADIATION; SECOND CANCER; SECONDARY LEUKEMIA; THERAPY-RELATED LEUKEMIA;

DNA-DAMAGING DRUGS; RADIATION; SECONDARY LEUKEMIA; THERAPY-RELATED LEUKEMIA;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, RADIATION-INDUCED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, SECOND PRIMARY;

EID: 84907968160     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.08.002     Document Type: Editorial

References (20)

1. Morton L.M., Dores G.M., Tucker M.A., Kim C.J., Onel K., Gilbert E.S., et al. Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Blood 2013, 121:2996-3004.
2. Quintas-Cardama A., Daver N., Kim H., Dinardo C., Jabbour E., Kadia T., et al. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 2014, pii: S2152-2650(14)00093-7. 10.1016/j.clml.2014.03.001.
3. Aguiar R.C. Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal. Leuk Lymphoma 1998, 29:17-26. [Erratum in Leuk Lymphoma 1998;30(5-6):665].
4. Hsu W.L., Preston D.L., Soda M., Sugiyama H., Funamoto S., Kodama K., et al. The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001. Radiat Res 2013, 179:361-382.
5. Iwanaga M., Hsu W.L., Soda M., Takasaki Y., Tawara M., Joh T., et al. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol 2011, 29:428-434.
6. Magnander K., Elmroth K. Biological consequences of formation and repair of complex DNA damage. Cancer Lett 2012, 327:90-96.
7. Chakraborty S., Stark J.M., Sun C.L., Modi H., Chen W., O'Connor T.R., et al. Chronic myelogenous leukemia stem and progenitor cells demonstrate chromosomal instability related to repeated breakage-fusion-bridge cycles mediated by increased nonhomologous end joining. Blood 2012, 119:6187-6197.
8. NCRP Second primary cancers and cardiovascular disease after radiation therapy. Recommendations of the national council on radiation protection and measurements: Bethesda 2013, 170.
9. Little M.P. Leukaemia following childhood radiation exposure in the Japanese atomic bomb survivors and in medically exposed groups. Radiat Prot Dosim 2008, 132:156-165.
10. Travis L.B., Ng A.K., Allan J.M., Pui C.H., Kennedy A.R., Xu X.G., et al. Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst 2012, 104:357-370.
11. Curtis R.E., Boice J.D., Stovall M., Bernstein L., Holowaty E., Karjalainen S., et al. Relationship of leukemia risk to radiation dose following cancer of the uterine corpus. J Natl Cancer Inst 1994, 86:1315-1324.
12. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000 2006, vol. 05-5302. National Cancer Institute, NIH Bethesda, MD.
13. Finch S.C. Myelodysplasia and radiation. Radiat Res 2004, 161:603-606.
14. Curtis R.E., Boice J.D., Stovall M., Bernstein L., Greenberg R.S., Flannery J.T., et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992, 326:1745-1751.
15. van Leeuwen F.E. Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. Baillieres Clin Haematol 1996, 9:57-85.
16. Lichtman M.A. Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia. Oncologist 2008, 13:645-654.
17. Godley L.A., Larson R.A. Therapy-related myeloid leukemia. Semin Oncol 2008, 35:418-429.
18. Duesberg P., Mandrioli D., McCormack A., Nicholson J.M. Is carcinogenesis a form of speciation. Cell Cycle 2011, 10:2100-2114.
19. Radivoyevitch T., Kozubek S., Sachs R. Biologically based risk estimation for radiation-induced CML - inferences from BCR and ABL geometric distributions. Radiat Environ Biophys 2001, 40:1-9.
20. Aurer I., Juhbashi T., Sekine I., Tomonaga M., Gale R.P. Analysis of BCR/ABL abnormalities in mRNA from 20-year-old paraffin-embedded tissue for BCR/ABL rearrangement by polymerase chain reaction. Acta Haematol 1993, 90:5-7.